Advanced glycation end products and the kidney
暂无分享,去创建一个
G. Wolf | G. Stein | S. Franke | J. Bohlender
[1] D. Kass,et al. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. , 2004, American journal of hypertension.
[2] L. Cai,et al. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. , 2004, The American journal of pathology.
[3] C. Falcone,et al. Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. , 2004, International journal of molecular medicine.
[4] Mark E. Williams. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease , 2004, Current diabetes reports.
[5] R. Bucala,et al. AGEs activate mesangial TGF-b –Smad signaling via an angiotensin II type I receptor interaction , 2010 .
[6] A. Flyvbjerg,et al. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. , 2004, Endocrine reviews.
[7] Y. Tseng,et al. Aminoguanidine Prevents Fructose-Induced Arterial Stiffening in Wistar Rats: Aortic Impedance Analysis , 2004, Experimental biology and medicine.
[8] Merlin C. Thomas,et al. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. , 2004, Kidney international. Supplement.
[9] M. Cooper,et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. , 2004, Diabetes.
[10] R. de Caterina,et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. , 2004, Diabetes.
[11] J. Bernheim,et al. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. , 2004, Kidney international.
[12] M. Lagarde,et al. Bimodal Effect of Advanced Glycation End Products on Mesangial Cell Proliferation Is Mediated by Neutral Ceramidase Regulation and Endogenous Sphingolipids* , 2004, Journal of Biological Chemistry.
[13] J. He,et al. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] Ann Marie Schmidt,et al. Protein Glycation: A Firm Link to Endothelial Cell Dysfunction , 2004, Circulation research.
[15] Merlin C. Thomas,et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.
[16] P. Dentelli,et al. RAGE‐ and TGF‐ β receptor‐mediated signals converge on STAT5 and p21waf to control cell‐cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] J. Uribarri,et al. High Levels of Dietary Advanced Glycation End Products Transform Low-Dersity Lipoprotein Into a Potent Redox-Sensitive Mitogen-Activated Protein Kinase Stimulant in Diabetic Patients , 2004, Circulation.
[18] E. Frohlich,et al. Crosslink breakers: a new approach to cardiovascular therapy , 2004, Current opinion in cardiology.
[19] U. Ott,et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.
[20] R. Donato,et al. Amphoterin Stimulates Myogenesis and Counteracts the Antimyogenic Factors Basic Fibroblast Growth Factor and S100B via RAGE Binding , 2004, Molecular and Cellular Biology.
[21] M. Cooper,et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. , 2004, The American journal of pathology.
[22] E. Frohlich,et al. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. , 2004, American journal of hypertension.
[23] J. Schneider,et al. A 63bp deletion in the promoter of rage correlates with a decreased risk for nephropathy in patients with type 2 diabetes. , 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[24] D. Warnock,et al. Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. , 2004, Seminars in nephrology.
[25] L. Roberts,et al. Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. , 2004, Chemical research in toxicology.
[26] A. Schmidt,et al. S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)* , 2004, Journal of Biological Chemistry.
[27] Mark E. Williams,et al. Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy , 2004, American Journal of Nephrology.
[28] C. Krone,et al. Ascorbic acid, glycation, glycohemoglobin and aging. , 2004, Medical hypotheses.
[29] F. Ziyadeh. Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator , 2004 .
[30] Paul J Thornalley,et al. Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. , 2003, Biochemical Society transactions.
[31] R. Khalifah,et al. Modification of Proteins In Vitro by Physiological Levels of Glucose , 2003, Journal of Biological Chemistry.
[32] K. Preissner,et al. The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins , 2003, The Journal of experimental medicine.
[33] Paul J Thornalley. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. , 2003, Archives of biochemistry and biophysics.
[34] T. Metz,et al. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. , 2003, Archives of biochemistry and biophysics.
[35] P. D. de Groot,et al. Glycation Induces Formation of Amyloid Cross-β Structure in Albumin* , 2003, Journal of Biological Chemistry.
[36] T. Metz,et al. Pyridoxamine Traps Intermediates in Lipid Peroxidation Reactions in Vivo , 2003, Journal of Biological Chemistry.
[37] J. Kyriakis,et al. Phosphatidylinositol 3′-Kinase-dependent Activation of Renal Mesangial Cell Ki-Ras and ERK by Advanced Glycation End Products* , 2003, Journal of Biological Chemistry.
[38] K. Ingold,et al. Paradoxical Impact of Antioxidants on Post-Amadori Glycoxidation , 2003, Journal of Biological Chemistry.
[39] G. Stein,et al. Advanced glycation end-products pentosidine and N " -carboxymethyllysine are elevated in serum of patients with osteoporosis , 2003 .
[40] L. Lanting,et al. Regulation of Cyclooxygenase-2 Expression in Monocytes by Ligation of the Receptor for Advanced Glycation End Products* , 2003, Journal of Biological Chemistry.
[41] Xiaodan Wang,et al. S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. , 2003, Diabetes.
[42] G. Jerums,et al. The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[43] T. Spector,et al. Level of an advanced glycated end product is genetically determined: a study of normal twins. , 2003, Diabetes.
[44] M. Khamaisi,et al. The emerging role of VEGF in diabetic kidney disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[45] G. Pugliese,et al. Role of galectin-3 in diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.
[46] J. Baynes,et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.
[47] E. Topol,et al. Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury , 2003, Circulation.
[48] M. Nangaku,et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. , 2003, Journal of the American Society of Nephrology : JASN.
[49] S. Horiuchi,et al. Role of megalin in endocytosis of advanced glycation end products: implications for a novel protein binding to both megalin and advanced glycation end products. , 2003, Journal of the American Society of Nephrology : JASN.
[50] V. D’Agati,et al. Glucose , Glycation , and RAGE : Implications for Amplification of Cellular Dysfunction in Diabetic , 2003 .
[51] V. D’Agati,et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.
[52] T. Vogl,et al. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. , 2003, Trends in immunology.
[53] A. Heidland,et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products , 2003, Journal of Human Hypertension.
[54] M. Andrassy,et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. , 2003, The Journal of clinical investigation.
[55] S. Takasawa,et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.
[56] T. Wendt,et al. Are advanced glycation end products cardiovascular risk factors in patients with CRF? , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[57] H. Hammes,et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.
[58] Michael Stumvoll,et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. , 2003, Diabetes.
[59] A. Heidland,et al. Genotoxicity of advanced glycation end products in mammalian cells. , 2003, Cancer letters.
[60] S. Yamagishi,et al. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. , 2003, Kidney international.
[61] G. Stein,et al. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. , 2003, Clinical nephrology.
[62] D. Aronson. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes , 2003, Journal of hypertension.
[63] F. Pugliese,et al. Clinical Potential of Advanced Glycation End-Product Inhibitors in Diabetes Mellitus , 2003, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[64] A. Enomoto,et al. An inhibitor of advanced glycation end product formation reduces N epsilon-(carboxymethyl)lysine accumulation in glomeruli of diabetic rats. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[65] Xiaodan Wang,et al. B-RAGE – Mediated Augmentation of Angiotensin II – Induced Activation of JAK 2 in Vascular Smooth Muscle Cells Is Dependent on PLD 2 , 2003 .
[66] M. Cooper,et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. , 2002, Endocrinology.
[67] M. Andrassy,et al. Activation of tubular epithelial cells in diabetic nephropathy. , 2002, Diabetes.
[68] Masayoshi Takeuchi,et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[69] M. Hill,et al. Matrix protein glycation impairs agonist‐induced intracellular Ca2+ signaling in endothelial cells , 2002, Journal of cellular physiology.
[70] M. Nangaku,et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.
[71] S. Horiuchi,et al. Peroxynitrite induces formation of N( epsilon )-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. , 2002, Diabetes.
[72] S. Horiuchi,et al. Scavenger receptors that recognize advanced glycation end products. , 2002, Trends in cardiovascular medicine.
[73] T. Miyata,et al. Renal Proximal Tubular Metabolism of Protein-Linked Pentosidine, an Advanced Glycation End Product , 2002, Nephron.
[74] Z. Makita,et al. Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells* , 2002, Journal of Biological Chemistry.
[75] S. Hong,et al. Inhibiting albumin glycation in vivo ameliorates glomerular overexpression of TGF-beta1. , 2002, Kidney international.
[76] M. Steffes,et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.
[77] R. de Caterina,et al. Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses , 2002, Circulation.
[78] S. Horiuchi,et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). , 2002, Journal of diabetes and its complications.
[79] R. Atkins,et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.
[80] P. Grant,et al. Study of the -429 T/C and -374 T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease. , 2001, Diabetes care.
[81] R. Bucala,et al. Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy? , 2001, Molecular medicine.
[82] D. Hsu,et al. Accelerated diabetic glomerulopathy in galectin‐3/AGE receptor 3 knockout mice , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[83] A. Schmidt,et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.
[84] D. Kass,et al. Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker , 2001, Circulation.
[85] A. Heidland,et al. Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[86] M. Crow,et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. , 2001, Diabetes.
[87] G. Stein,et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[88] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[89] R. Tilton,et al. Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes Materials and Methods Laboratory Animals , 2022 .
[90] G. Jerums,et al. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. , 2001, Clinical science.
[91] T. Henle,et al. Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteins. , 2001, Kidney international. Supplement.
[92] S. Jain,et al. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. , 2001, Free radical biology & medicine.
[93] F. Ziyadeh,et al. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. , 2001, Kidney international.
[94] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[95] G. Jerums,et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. , 2000, Journal of the American Society of Nephrology : JASN.
[96] G. Jerums,et al. Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.
[97] Alan W. Stitt,et al. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease. , 2000, Kidney international.
[98] T. Miyata,et al. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. , 2000, Journal of the American Society of Nephrology : JASN.
[99] G. Wolf. Cell cycle regulation in diabetic nephropathy. , 2000, Kidney international. Supplement.
[100] T. Miyata,et al. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. , 2000, Journal of the American Society of Nephrology : JASN.
[101] V. D’Agati,et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.
[102] P. Oturai,et al. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. , 2000, Metabolism: clinical and experimental.
[103] C. Soto,et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis , 2000, Nature Medicine.
[104] Hiroshi Yamamoto,et al. The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[105] F. Ziyadeh,et al. Inhibiting Albumin Glycation Ameliorates Diabetic Nephropathy in the db/db Mouse , 2000, Nephron Experimental Nephrology.
[106] M. Cooper,et al. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation , 2000, Diabetologia.
[107] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[108] Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis. , 2000, Journal of nephrology.
[109] H. Yamamoto,et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. , 2000, The Journal of biological chemistry.
[110] M. Cooper,et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.
[111] T. Kislinger,et al. N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.
[112] P. Malherbe,et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.
[113] Z. Varghese,et al. Human mesangial cells express inducible macrophage scavenger receptor. , 1999, Kidney international.
[114] E. Ritz,et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[115] H. Huttunen,et al. Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.
[116] A. Heidland,et al. Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan , 1999, Mineral and Electrolyte Metabolism.
[117] A. Teti,et al. Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.
[118] M. Neurath,et al. RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.
[119] F. Ziyadeh,et al. Glycated albumin stimulation of PKC-β activity is linked to increased collagen IV in mesangial cells. , 1999, American journal of physiology. Renal physiology.
[120] T. Miyata,et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.
[121] Y. Yamori,et al. Biomechanical properties and chemical composition of the aorta in genetic hypertensive rats. , 1999, Journal of hypertension.
[122] Alan W. Stitt,et al. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. , 1999, Biochemical and biophysical research communications.
[123] G. Jerums,et al. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. , 1999, Kidney international.
[124] K. Maeda,et al. Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. , 1999, Biochemical and biophysical research communications.
[125] M. Jadoul,et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. , 1998, Journal of the American Society of Nephrology : JASN.
[126] T. Miyata,et al. Alterations in non-enzymatic biochemistry in uremia: carbonyl stress , 1998 .
[127] T. Miyata,et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.
[128] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[129] P. Grant,et al. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. , 1998, Diabetes.
[130] H. Gröne,et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. , 1998, Journal of the American Society of Nephrology : JASN.
[131] T. Miyata,et al. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia. , 1998, Biochemical and biophysical research communications.
[132] M. Huijberts,et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[133] Paul J Thornalley,et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. , 1998, The Journal of clinical investigation.
[134] M. Nangaku,et al. Renal catabolism of advanced glycation end products: the fate of pentosidine. , 1998, Kidney international.
[135] 杉山 敏. Plasma level of pentosidine, an advanced glycation end product, in diabetic patients , 1998 .
[136] 堀江 勝智. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions : implication for glycoxidative stress in the pathogenesis of diabetic nephropathy , 1998 .
[137] J. Mott,et al. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. , 1997, Kidney international.
[138] A. Schmidt,et al. Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.
[139] A. Schmidt,et al. Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products* , 1997, The Journal of Biological Chemistry.
[140] M. Cooper,et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury , 1997, Diabetologia.
[141] K. Kushida,et al. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. , 1997, British journal of rheumatology.
[142] M. Kasuga,et al. Inhibitory effects of tenilsetam on the Maillard reaction. , 1997, Endocrinology.
[143] Y. Wada,et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. , 1997, Kidney international.
[144] T. Miyazaki,et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. , 1997, The Journal of clinical investigation.
[145] C van Ypersele de Strihou,et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. , 1997, Kidney international.
[146] S. L. Hazen,et al. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammat , 1997, The Journal of clinical investigation.
[147] J. Ménard,et al. High human renin hypertension in transgenic rats. , 1997, Hypertension.
[148] Alan W. Stitt,et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[149] T. Miyata,et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. , 1996, The Journal of clinical investigation.
[150] C van Ypersele de Strihou,et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.
[151] M. Brownlee,et al. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. , 1996, The Journal of clinical investigation.
[152] T. Miyazaki,et al. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. , 1996, Kidney international.
[153] Yong Ming Li,et al. Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex , 1995, Molecular medicine.
[154] E. Ritz,et al. Expression of receptors for advanced glycosylated end-products in renal disease. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[155] A. Gugliucci,et al. Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[156] F N Ziyadeh,et al. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. , 1995, The Journal of clinical investigation.
[157] Yong Ming Li,et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[158] G. Striker,et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[159] S. Grundy,et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[160] T. Ikemura,et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. , 1994, Genomics.
[161] M. Brownlee,et al. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.
[162] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[163] K. Sharma,et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. , 1994, The Journal of clinical investigation.
[164] Y. Zou,et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.
[165] T. Lyons,et al. Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.
[166] K. Sharma,et al. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β , 1992 .
[167] W. Hurley,et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. , 1992, The Journal of biological chemistry.
[168] K. O. Elliston,et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.
[169] E. Tsilibary,et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. , 1992, The Journal of biological chemistry.
[170] M. V. van Boekel,et al. Glycation of human serum albumin: inhibition by Diclofenac. , 1992, Biochimica et biophysica acta.
[171] E. Friedman,et al. Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.
[172] K. Tracey,et al. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.
[173] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[174] B. Mcverry,et al. PRODUCTION OF PSEUDODIABETIC RENAL GLOMERULAR CHANGES IN MICE AFTER REPEATED INJECTIONS OF GLUCOSYLATED PROTEINS , 1980, The Lancet.